Sanofi Gross Margin 2010-2023 | SNY
Current and historical gross margin for Sanofi (SNY) over the last 10 years. The current gross profit margin for Sanofi as of December 31, 2023 is %.
| Sanofi Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2023-12-31 |
$50.27B |
$34.86B |
69.35% |
| 2023-09-30 |
$49.01B |
$34.08B |
69.53% |
| 2023-06-30 |
$48.42B |
$33.81B |
69.83% |
| 2023-03-31 |
$48.20B |
$33.70B |
69.91% |
| 2022-12-31 |
$47.82B |
$33.39B |
69.83% |
| 2022-09-30 |
$48.72B |
$34.35B |
70.51% |
| 2022-03-31 |
$34.76B |
$24.48B |
70.41% |
| 2021-09-30 |
$35.03B |
$24.26B |
69.26% |
| 2021-03-31 |
$43.57B |
$29.98B |
68.80% |
| 2020-09-30 |
$42.75B |
$29.42B |
68.82% |
| 2020-03-31 |
$41.19B |
$28.45B |
69.06% |
| 2019-09-30 |
$41.49B |
$28.27B |
68.15% |
| 2019-03-31 |
$41.50B |
$28.41B |
68.47% |
| 2018-03-31 |
$41.43B |
$28.14B |
67.93% |
| 2017-12-31 |
$40.92B |
$27.80B |
67.93% |
| 2017-09-30 |
$40.25B |
$27.56B |
68.47% |
| 2017-06-30 |
$39.59B |
$27.15B |
68.59% |
| 2017-03-31 |
$39.14B |
$27.03B |
69.06% |
| 2016-12-31 |
$38.41B |
$26.57B |
69.17% |
| 2016-09-30 |
$39.27B |
$27.29B |
69.49% |
| 2016-06-30 |
$39.37B |
$27.23B |
69.17% |
| 2016-03-31 |
$41.16B |
$28.29B |
68.75% |
| 2015-09-30 |
$42.97B |
$29.31B |
68.22% |
| 2015-06-30 |
$43.92B |
$30.08B |
68.50% |
| 2014-06-30 |
$44.70B |
$30.67B |
68.62% |
| 2013-06-30 |
$45.22B |
$31.02B |
68.59% |
| 2012-06-30 |
$46.75B |
$31.94B |
68.33% |
| 2012-03-31 |
$47.10B |
$31.70B |
67.31% |
| 2011-12-31 |
$47.27B |
$32.09B |
67.88% |
| 2011-09-30 |
$45.65B |
$31.06B |
68.05% |
| 2011-06-30 |
$44.35B |
$30.90B |
69.68% |
| 2011-03-31 |
$42.93B |
$30.94B |
72.07% |
| 2010-12-31 |
$41.26B |
$29.68B |
71.95% |
| 2010-09-30 |
$41.28B |
$29.76B |
72.09% |
| 2010-06-30 |
$41.42B |
$29.96B |
72.33% |
| 2010-03-31 |
$41.35B |
$30.02B |
72.59% |
| 2009-12-31 |
$40.79B |
$29.80B |
73.06% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$114.819B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
